32. Benedetti, S., et al., The effects of Acyclovir administration
to NCI-H1975 non-small cell lung cancer cells. Toxicol In Vitro, 2022.
79: p. 105301.
33. Özdemir, M.D. and D. Göktürk, The concurrent effect of
acyclovir and rosemary on glioblastoma cell culture. Cell Mol Biol
(Noisy-le-grand), 2019. 65 (3): p. 66-71.
34. Asano-Mori, Y., et al., Clinical features of late
cytomegalovirus infection after hematopoietic stem cell
transplantation. Int J Hematol, 2008. 87 (3): p. 310-8.
35. Asahi, T., et al., Valacyclovir neurotoxicity: clinical
experience and review of the literature. Eur J Neurol, 2009.16 (4): p. 457-60.
36. Yu, R.J., et al., Emerging Causes of Drug-Induced Anaphylaxis:
A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event
Reporting System (FAERS). J Allergy Clin Immunol Pract, 2021.9 (2): p. 819-829.e2.
37. Golomb, B.A., et al., Physician response to patient reports of
adverse drug effects: implications for patient-targeted adverse effect
surveillance. Drug Saf, 2007. 30 (8): p. 669-75.
38. Hazell, L. and S.A. Shakir, Under-reporting of adverse drug
reactions : a systematic review. Drug Saf, 2006. 29 (5): p.
385-96.